Press "Enter" to skip to content

Europe Glucagon like Peptide – 1 (GLP – 1) Agonists Market 2019: Comprehensive Analysis by Top Key Companies, Industry Growth, Size, Share, Market Insights, Sales Volume and Forecast to 2024

Europe

The “Europe Glucagon like Peptide – 1 (GLP – 1) Agonists Market” research report 2019-2024 delivers comprehensive information and valuable insights about the Europe Glucagon like Peptide – 1 (GLP – 1) Agonists industry. The information available in the Europe Glucagon like Peptide – 1 (GLP – 1) Agonists market report is not only based on the facts but also on the case studies, which analysts have included to convey appropriate information to the clients in a well-versed manner. Europe Glucagon like Peptide – 1 (GLP – 1) Agonists market report includes valuable information to assist new entrants, as well as established players, to understand the prevailing trends in the market.

Some Companies Are Covered in the Europe Glucagon like Peptide – 1 (GLP – 1) Agonists Market:

  • Novo Nordisk
  • Sanofi
  • Eli Lilly
  • AstraZeneca

    Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/13999723

    Market Overview:

  • The Europe glucagon-like peptide-1 (GLP-1) market is expected to witness tremendous growth during the forecast period (2019-2024), with a CAGR of 14.5%, mainly as a result of new drug launches.
  • Europe has approximately 56.3 million adults living with diabetes, and this number is expected to reach 70 million by 2023, which would represent around 10% of the total population of Europe.
  • Europe’s expenditure on diabetes is 9% of its total healthcare expenditure. Spending on diabetes largely varies among countries in Europe. It ranges from EUR 312 per capita in the Republic of Macedonia, to EUR 6,896 per capita in Norway.
  • Similarly, the prevalence is also highly varied across Europe, ranging from 2.8% in Albania to 9.8% in Portugal.
  • In high-income countries, diabetes is one of the leading causes of cardiovascular disease, blindness, kidney failure, and lower limb amputation.
  • The European region suffers from a high burden of diabetes, and its adverse health and economic consequences.
  • The disease is viewed as a serious threat, not just from a public health perspective, but also from a development perspective.
  • With risk factors, such as obesity increasing, and progressively aging populations, the diabetes epidemic is growing, especially in low- and middle-income countries of the region. It is one of the most common chronic diseases in the United Kingdom.

    Scope of the Report:

  • The market is segmented by the drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia), and by geography.

    Reasons for Buying Europe Glucagon like Peptide – 1 (GLP – 1) Agonists Market Report:

    • This report provides pin-point analysis for changing competitive dynamics
    • It provides a forward looking perspective on different factors driving or restraining market growth
    • It provides a five-year forecast assessed on the basis of how the market is predicted to grow
    • It helps in understanding the key product segments and their future
    • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
    • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

    For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/13999723

    Key Market Trends: – Ever Increasing Burden of Diabetes in the European Region

    As there is an exponential growth of the diabetes population, year on year, especially of type-2 diabetes, new innovative drugs are emerging in the market, for the ease of access to the patients.
    With the increase in the diabetes population, the need and demand for diabetes drugs are expected to increase.
    Other factors, such as better adoption than other therapies and government initiatives, are driving the diabetes drugs market.

    Germany to Dominate the Europe GLP-1 Market

    Among the studied countries, Germany is expected to lead the market, with a considerable 27.25% of the market share, followed by France.
    Victoza holds the highest market share in the Europe region, and a similar trend is seen in Germany too. Victoza is a once-daily injection, used to control blood glucose levels by enhancing glucose-dependent insulin secretion by beta cells, suppressing inappropriate elevated glucagon secretion.
    Trulicity is expected to have the highest growth during the forecast period (2019-2024) in the Europe region.

    Europe Glucagon like Peptide – 1 (GLP – 1) Agonists Market Report Provides Comprehensive Analysis of:

    • Functional market industry outline
    • Up and downstream industry examination
    • Channels and propositions believability
    • Market challenge by key players
    • Enhancement suggestions examination

    Purchase this Report (Price 4000 USD for single user license) – https://www.industryresearch.co/purchase/13999723

    Report Highlights:

    • Market Dynamics – Drivers, Restraints, and Opportunities
    • Market Segmentation – Types, Applications, Regions, and Technology
    • Market Trends
    • Competitive Landscape
    • SWOT Analysis and Porter’s Five Forces Analysis

    Detailed TOC of Europe Glucagon like Peptide – 1 (GLP – 1) Agonists Market Report 2019-2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Drug
    5.1.1 Exenatide
    5.1.1.1 Byetta (Value and Volume 2012-2024)
    5.1.1.2 Bydureon (Value and Volume 2012-2024)
    5.1.2 Liraglutide
    5.1.2.1 Victoza (Value and Volume 2012-2024)
    5.1.3 Lixisenatide
    5.1.3.1 Lyxumia (Value and Volume 2012-2024)
    5.1.4 Dulaglutide
    5.1.4.1 Trulicity (Value and Volume 2012-2024)
    5.2 Geography
    5.2.1 Europe
    5.2.1.1 Germany (Value and Volume 2012-2024)
    5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.1.2 Spain (Value and Volume 2012-2024)
    5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.1.3 Italy (Value and Volume 2012-2024)
    5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly and AstraZeneca)
    5.2.1.4 France (Value and Volume 2012-2024)
    5.2.1.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide and Dulaglutide)
    5.2.1.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.1.5 UK (Value and Volume 2012-2024)
    5.2.1.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.1.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.1.6 Russia (Value and Volume 2012-2024)
    5.2.1.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.1.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.1.7 Rest of Europe (Value and Volume 2012-2024)
    5.2.1.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.1.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

    6 MARKET INDICATORS
    6.1 Type-1 Diabetes Population (2012-2024)
    6.2 Type-2 Diabetes Population (2012-2024)

    7 COMPETITIVE LANDSCAPE
    7.1 COMPANY PROFILES
    7.1.1 Novo Nordisk
    7.1.2 Sanofi
    7.1.3 Eli Lilly
    7.1.4 AstraZeneca
    7.2 MARKET SHARE ANALYSIS
    7.2.1 Novo Nordisk
    7.2.2 Sanofi
    7.2.3 Eli Lilly
    7.2.4 AstraZeneca

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Margarine Market Share, Size 2019 Developing Rapidly with Recent Trends, Development, Revenue, Demand and Forecast to 2026 | Says Industryresearch.Biz

    Global Glass Encapsulation Market 2019 Industry Size, Growth Factor, Key Drivers, Segments, Share and Demand Analysis and 2024 Forecast Research Report,

    Wearable Technology Market Size 2019: Global Study by Competition Landscape, SWOT Analysis, Projections, Services and Solutions 2025

    Antidepressant Market 2019 Global Leading Players, Industry Updates, Future Growth, Business Prospects, Forthcoming Developments and Future Investments by Forecast to 2024

  • Be First to Comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *